Replies to post #114567 on Biotech Values

[linhdtu]

DD handicapped the mCopax event as such :
---------------
Absent any new information, I rate the cumulative probability of FDA approval of NVS/MNTA’s Copaxone ANDA by the end of 2011, 2012, 2013, and 2014, respectively, at 42%, 68%, 78%, and 84%. JMHO, FWIW
---------------
My own opinion is that he is being conservative with his odds, which does not hurt btw and which is the right way to do it.

[HattieTheWitch]

At what time what this said (in the audio file)?

Thank you.

[DewDiligence]

That’s a typo in the Seeking Alpha transcript. The word in question is “active” (not “after”). I.e., the Copaxone ANDA is under active review by the FDA.

Edit: I see that Hattie already confirmed this.